US81642T2096
US81642T2096
SELLAS Life Sciences Group, Inc
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 2.35B EUR | 2.98B EUR | 767.04M EUR | 577.2M EUR |
Enterprise Value | 2.14B EUR | 2.84B EUR | 660.81M EUR | 506.41M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -116.5x | -- | -- | -- |
Price to Sales | -- | -- | -- | -- |
Price to Book | 17.08x | 21.65x | 7.14x | 8.14x |
EV/Revenue | -- | -- | -- | -- |
EV/EBITDA | -- | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -0.7% | -0.95% | -3.67% | -3.35% |